Quick Answer
Travere Therapeutics, Inc. reported R&D Expense of $140.96 million for fiscal year 2019.
Travere Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2019 | $140.96M | +13.9% |
| 2018 | $123.76M | +58.3% |
| 2017 | $78.17M | +10.4% |
| 2016 | $70.82M | +40.4% |
| 2015 | $50.43M | +5.5% |
| 2014 | $47.80M | +574.7% |
| 2013 | $7.08M | +969.3% |
| 2012 | $662.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $48.41M | +49.6% | -6.6% |
| June 30, 2021 | $51.81M | +68.3% | +8.1% |
| March 31, 2021 | $47.95M | +58.5% | +48.2% |
| September 30, 2020 | $32.35M | -2.6% | +5.1% |
| June 30, 2020 | $30.79M | -18.8% | +1.8% |
| March 31, 2020 | $30.25M | -9.6% | -8.9% |
| September 30, 2019 | $33.22M | +2.4% | -12.4% |
| June 30, 2019 | $37.93M | +10.1% | +13.4% |
- Travere Therapeutics, Inc. showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2019 period, Travere Therapeutics, Inc.’s r&d expense has grown by 21177.4% (from $662.5 thousand to $140.96 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 24, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: